AGAP2

AGAP2 is a multi-domain ArfGAP protein that functions as a central regulator of endosomal membrane trafficking and focal adhesion dynamics. It interacts with AP-1 on Rab4-positive endosomes to promote fast recycling of transferrin receptor (PMID:16079295), mediates Arf1-dependent retrograde transport from early endosomes to the TGN (PMID:20551179), and controls β2-adrenergic receptor recycling through a complex with β-arrestins (PMID:23527545). AGAP2 binds FAK via its PH domain to drive focal adhesion turnover independently of its GAP activity, while the scaffolding protein RACK1 bridges AGAP2 to FAK in neuronal growth cones to regulate neurite outgrowth (PMID:19318351, PMID:24056044). Beyond trafficking, AGAP2 sustains TGFβ receptor recycling and profibrogenic signaling in hepatic stellate cells (PMID:30660615), promotes Fcγ receptor–mediated phagocytosis through GAP-domain–dependent recruitment to phagocytic cups (PMID:36611866), and drives lipid metabolic reprogramming in AML by inhibiting the AMPKα/ACC pathway under transcriptional repression by NR2F2 (PMID:41838329).

1. 2005 High

   The question of which trafficking compartment AGAP2 operates on was answered by showing it binds AP-1 and localizes to Rab4-positive endosomes, establishing AGAP2 as a regulator of fast endosomal recycling distinct from the AP-3-associated paralog AGAP1.

   Evidence Co-localization, direct interaction assay, and transferrin recycling assay with overexpression in cultured cells

   PMID:16079295

   Open questions at the time

   • The endogenous cargo spectrum regulated by AGAP2-AP-1 interaction is undefined
   • Whether AGAP2 GAP activity is required for the recycling function was not tested
   • Rab4 epistasis experiments were not performed
2. 2009 High

   The mechanism by which AGAP2 influences cell adhesion was resolved: its PH domain directly binds FAK independently of FAK activation state, and AGAP2 promotes focal adhesion dissolution through a GAP-independent, possibly GLD-dependent mechanism.

   Evidence Co-immunoprecipitation, domain mutants, RNA interference knockdown and overexpression with focal adhesion imaging in HeLa cells

   PMID:19318351

   Open questions at the time

   • The specific contribution of the G protein-like domain to focal adhesion turnover was not fully dissected
   • In vivo relevance of AGAP2-FAK interaction to cell migration was not demonstrated
3. 2010 High

   A previously unrecognized role for AGAP2 in retrograde early-endosome-to-TGN transport was established by showing that AGAP2 depletion traps Shiga toxin, TGN46, and mannose-6-phosphate receptor in early endosomes, and that this pathway requires Arf1 but not Arf6.

   Evidence siRNA depletion, dominant-negative Arf mutants, toxin trafficking and colocalization imaging

   PMID:20551179

   Open questions at the time

   • Whether AGAP2 GAP activity toward Arf1 is catalytically required for retrograde sorting was not directly tested
   • The coat or adaptor complex partnering with AGAP2 at this step is unknown
4. 2013 High

   AGAP2's trafficking role was extended to GPCR biology: it complexes with β-arrestins and controls β2-adrenergic receptor recycling and ERK signaling, linking its endosomal function to receptor-mediated signal transduction.

   Evidence Co-immunoprecipitation with β-arrestins, receptor recycling assay, ERK phosphorylation measurement upon overexpression and knockdown

   PMID:23527545

   Open questions at the time

   • Whether AGAP2 acts on the sorting or tubulation step of receptor recycling is unresolved
   • Generality to other GPCRs was not tested
5. 2013 High

   RACK1 was identified as a scaffold that bridges AGAP2 to FAK in neuronal growth cones, resolving how AGAP2-FAK signaling is spatially organized to control neurite outgrowth.

   Evidence Mass spectrometry, immunoprecipitation, siRNA knockdown with FAK phosphorylation and neurite outgrowth assays in neuronal cells

   PMID:24056044

   Open questions at the time

   • Upstream signals regulating RACK1-AGAP2 assembly are unknown
   • Whether the RACK1-AGAP2-FAK complex participates in non-neuronal cell migration was not addressed
6. 2019 High

   AGAP2 was placed within the hepatic fibrosis signaling network: TGFβ1 transcriptionally induces AGAP2, which in turn sustains TGFβR2 recycling and profibrogenic gene expression through FAK and MEK1, revealing a positive feedback loop.

   Evidence siRNA knockdown and overexpression in hepatic stellate cells, promoter reporter, receptor trafficking assay, in vivo CCl4 fibrosis model

   PMID:30660615

   Open questions at the time

   • Whether AGAP2 directly regulates TGFβR2 sorting or acts indirectly through general recycling machinery is unclear
   • The promoter elements mediating TGFβ1-induced AGAP2 transcription were not mapped
7. 2019 Medium

   The transcription factor SP1 was identified as a direct driver of AGAP2 expression, with RARα/RXRα and PCAF also occupying the promoter, establishing the first transcriptional regulatory framework for AGAP2.

   Evidence ChIP, promoter reporter assay, SP1 siRNA knockdown, ATRA and curcumin treatments in cancer cell lines

   PMID:30674964

   Open questions at the time

   • Single lab study; independent validation needed
   • Whether SP1 regulation of AGAP2 is cell-type-specific was not assessed
   • Functional contribution of PCAF-mediated acetylation at the AGAP2 locus is unknown
8. 2022 Medium

   AGAP2 was shown to promote Fcγ receptor–mediated phagocytosis, with the GAP domain—but not its catalytic activity—required for recruitment to phagocytic cups, extending AGAP2 function to innate immunity.

   Evidence Domain deletion and point mutants, phagocytosis assay, siRNA knockdown in PLB-985 neutrophil-like cells, phosphorylation detection in primary neutrophils

   PMID:36611866

   Open questions at the time

   • Single lab; independent replication needed
   • The binding partner recognized by the GAP domain at the phagocytic cup is unidentified
   • Whether AGAP2 acts upstream or downstream of Arf1 during phagocytosis is unresolved
9. 2022 Medium

   Pharmacological suppression of AGAP2 by demethylzeylasteral phenocopied AGAP2 knockdown in hepatic stellate cells, reducing FAK/AKT phosphorylation and fibrosis, providing orthogonal support for the AGAP2–FAK–fibrosis axis.

   Evidence RNA-seq, Western blot, immunofluorescence, in vitro and in vivo CCl4 fibrosis model

   PMID:35905567

   Open questions at the time

   • Mechanistic attribution relies on AGAP2 suppression by a compound that likely has additional targets
   • Direct rescue with AGAP2 overexpression was not performed
10. 2026 Medium

    AGAP2 was linked to lipid metabolic reprogramming in AML: NR2F2 transcriptionally represses AGAP2, and AGAP2 promotes lipid deposition and leukemia progression by inhibiting the AMPKα/ACC pathway, revealing a non-trafficking metabolic role.

    Evidence Promoter binding assay, overexpression/knockdown rescue experiments, mRNA-seq, Filipin III staining, in vivo AML mouse model

    PMID:41838329

    Open questions at the time

    • Single lab; awaits independent confirmation
    • Mechanism by which AGAP2 inhibits AMPKα is unknown—direct binding or indirect
    • Whether the lipid metabolic role is unique to AML or generalizable is untested

• A structural understanding of how AGAP2's individual domains (GLD, PH, ArfGAP, ankyrin repeats) cooperate to partition its distinct trafficking, adhesion, phagocytic, and metabolic functions remains unresolved.
• No high-resolution structure of full-length AGAP2 or multi-domain constructs exists
• Allosteric regulation between the GLD and GAP domains has not been characterized
• Physiological Arf substrate specificity in each functional context is undefined